ARTICLE | Finance
Plus: Akeso’s bispecific gets priority review in China, and updates on Merck-Eisai, Sandoz’s Tysabri biosimilar and the IRA
By BioCentury Staff
August 25, 2023 9:40 PM UTC
Radiotherapeutics company RayzeBio Inc. and neuroscience company Neumora Therapeutics Inc. are aiming to be among the next biotechs to go public on NASDAQ, testing a market that has been slow for new listings since early 2022 but has shown signs of life more recently.
RayzeBio filed a prospectus Thursday to conduct an offering underwritten by J.P. Morgan, Jefferies, Evercore ISI and Truist. RayzeBio’s lead program is a peptide conjugate radiotherapeutic that delivers Actinium-225 to tumors expressing SSTR2; the company started a Phase III trial in May to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Top shareholders include Viking Global Investors, Versant Ventures, venBio, Venrock and PeptiDream Inc. (Tokyo:4587). Versant and venBio led RayzeBio’s 2020 series A round, and Venrock led its series B later the same year…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- ChartPrime. Elevate your Trading Game with ChartPrime. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: https://www.biocentury.com/article/649038/aug-25-quick-takes-rayzebio-neumora-prepare-for-ipos